骨髓增生异常综合征治疗药物——pevonedistat
A therapeutic drug for myelodysplastic syndrome:pevonedistat
王堂乐 1王鹏 1韩语轩 1郭兆霖 1曹爽 1刘彦2
作者信息
- 1. 武汉工程大学 化工与制药学院,武汉 430205
- 2. 国家药品监督管理局 药品审评中心,北京 100022
- 折叠
摘要
pevonedistat是一种新型神经前体细胞表达发育下调蛋白8(NEDD8)激活酶抑制剂,其可通过干扰NEDD8激活酶的生物活性破坏蛋白,从而导致肿瘤细胞死亡.pevonedistat对骨髓增生异常综合征及相关血液学肿瘤疾病的治疗效果已获得多个临床研究验证.本文对pevonedistat的基本信息、作用机制、药动学、临床疗效及安全性等进行综述,旨在为临床应用提供参考.
Abstract
Pevonedistat is a novel inhibitor of neuronal precursor cell-expressed developmentally down-regulated pro-tein 8(NEDD8)activating enzyme.The drug disrupts the protein and causes tumor cell apoptosis by interfering with the biolog-ical activity of the NEDD8 activating enzyme.The therapeutic effect of pevonedistat on myelodysplastic syndrome and related hematological tumor diseases has been validated by multiple clinical studies.This article reviews the basic information,mecha-nism of action,pharmacokinetics,clinical efficacy,and safety of pevonedistat,aiming to provide a reference for clinical appli-cations.
关键词
pevonedistat/骨髓增生异常综合征/急性髓系白血病/神经前体细胞表达发育下调蛋白8激活酶抑制剂Key words
pevonedistat/myelodysplastic syndrome/acute myeloid leukemia/neural precursor cell-expressed develop-mentally down-regulated protein 8 activating enzyme引用本文复制引用
基金项目
武汉工程大学研究生教育创新基金(CX2022025)
出版年
2024
NETL
NSTL
万方数据